Several bispecific antibodies have been developed and are clinically efficacious in pediatric cancers, most impressively in leukemias with the anti-CD19/anti-CD3-targeting bispecific antibody blinatumomab (Gore et al. 2018, von Stackelberg et al. 2016). Here, CD19 is linked to leukemia.